Raza Bokhari - 22 Jul 2025 Form 4 Insider Report for Medicus Pharma Ltd. (MDCX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MDCX
Reported as of: 22 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jul 2025, 17:11:49 UTC
Prior SEC filing: 10 Feb 2025
Next SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Raza Bokhari

Key filing fact

Raza Bokhari filed Form 4 for Medicus Pharma Ltd. (MDCX) on 24 Jul 2025.

Key facts

This page summarizes Raza Bokhari's Form 4 filing for Medicus Pharma Ltd. (MDCX).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 24 Jul 2025, 17:11.

Change

Previous filing in this sequence was filed on 10 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001660525 Primary reporting owner

Bokhari Raza

Relationship: Chief Executive Officer, Director
Address: 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN
Signature: /s/ Raza Bokhari
Signature date: 24 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDCX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 22 Jul 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 250,000
Exercise price: $3.08
Footnotes: F3

MDCX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 50,000
Date: 22 Jul 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $2.75
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.

Footnote F2

The board of directors of Medicus Pharma Ltd. (the ?Board?) approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest quarterly in four equal installments over one year from the initial grant date of December 17, 2024. All these options are now vested.

Footnote F3

The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.